A number of disease- or host-related markers have been proposed to predict treatment outcome in relapsed/refractory Hodgkin lymphoma (HL). In this issue of Blood, Moskowitz et al demonstrate that fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) performed in sequence during second-line treatment recapitulates all of them.1
CITATION STYLE
Gallamini, A. (2017, November 16). Relapsed/refractory HL: FDG-PET is the trump card. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-09-806299
Mendeley helps you to discover research relevant for your work.